section name header

Pronunciation

glek-A-pre-vir/pi-BRENT-as-vir

Classifications

Therapeutic Classification: antivirals

Pharmacologic Classification: NS5A inhibitors, protease inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Glecaprevir

Absorption: Well absorbed following oral administration; absorption by high-fat meal.

Distribution: Unknown.

Protein Binding: 97.5%.

Metabolism/Excretion: Partially metabolized by the liver via the CYP3A4 isoenzyme; 92% excreted in feces and <1% eliminated in urine.

Half-life: 6 hr.

Pibrentasvir

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: >99.9%.

Metabolism/Excretion: Not metabolized; 97% excreted in feces.

Half-life: 13 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
glecaprevir (PO)unknown5 hr24 hr
pibrentasvir (PO)unknown5 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: pruritus.

GI: diarrhea, HBV reactivation, hyperbilirubinemia, nausea.

Neuro: fatigue, headache.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Mavyret

Canadian Brand Names

Maviret